Our goal is to provide doctors with a tool to remove harmful components from the bloodstream to treat blood-borne diseases.

Keep In Touch

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood-borne diseases. The company’s initial targets are Sepsis, Leukaemia and Malaria. Located in the Translation and Innovation Hub in White City, the company is preparing for first-in-man trials in 2020.

Our multidisciplinary team has experience across various fields of science and technology development.

 

MediSieve expands its research into treating COVID-19

MediSieve expands its research into treating COVID-19
April 29, 2020

Recent studies show that patients with the most serious forms of the coronavirus had high levels of something called IL-6, a common inflammatory cytokine, which MediSieve has previously encountered while researching sepsis and cytokine storms.
COVID-19 Response

COVID-19 Response
April 03, 2020

Recent clinical data has shown that >50 per cent of hospitalised COVID-19 patients develop cytokine storm syndromes, and that these are a major driver of mortality.